| To: Eye who wrote (190) | 1/17/2001 1:00:48 PM | | From: Cindy Powell | | | | You are wise to shun the pennies and just be a watcher. MLSC has been one of my more disappointing holdings, and I wish I was just a watcher rather than a shareholder. I'm done with pennies even with play money. I could have had more fun playing the slots! There are too many good nasdaq companies that aren't fraught with the challenges and uphill battles that pennies have. Not to say that alot of nasdaq companies aren't junk, as evidenced by last years dot com collapse, but pennies are just too risky in my opinion.
Here are a couple of new press releases that shows that MLSC is still working towards their goals. Hopefully, this stock will bounce back.
Take care,
Cindy |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Cindy Powell who wrote (191) | 1/17/2001 1:03:44 PM | | From: Cindy Powell | | | | Study Validates Microbicidal Effectiveness of Medical Discoveries, Inc. Novel Drug, 'MDI-P'
Peer-Reviewed Research Paper Details Sterilization Effectiveness
SALT LAKE CITY, Jan. 10 /PRNewswire/ -- A new study on the microbe-killing properties of MDI-P, using four microorganisms that are difficult to eradicate in the hospital environment, has been completed at the Infectious Diseases Section of the Stratton VA Medical Center in Albany, New York.
The infectious diseases research group, headed by Aldona Baltch, M.D., found that MDI-P is a highly effective microbicide for the organisms studied. The microbicidal effect of MDI-P is very rapid and it retains high microbicidal activity even in the presence of 50% human blood serum. There are no obvious adverse effects on the tissues of mice injected intravenously with MDI-P and preliminary results suggest that the microbicidal activity of MDI-P is relatively stable. The results of this study suggest that MDI-P may be useful for disinfection of inanimate surfaces, cold sterilization of medical devices, antisepsis, and irrigation therapy for wounds and ulcers.
The findings of Dr. Baltch's group have been published in ``The American Journal Of Infection Control'' (AJIC 2000;28:251-7), the official journal of the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC). ``AJIC'' covers key topics and issues in the field of infection control, with peer-reviewed articles ranging from practical, clinically applicable topics to original, cutting-edge scientific research. ``AJIC'' is a highly respected resource on infection control, epidemiology, quality assurance, occupational health, and disease prevention and is widely read by infection control professionals, including physicians, nurses, and epidemiologists.
In addition to the ``AJIC'' paper, Dr. Baltch's work on MDI-P has been published in the abstracts of, and presented at, the 97th and 98th Annual Meetings of The American Society of Microbiology. The research was supported by Medical Discoveries, Inc. and, in part, by the Research Service of the Veterans Administration.
The four microorganisms used in the studies were Pseudomonas aeruginosa, Staphylococcus aureus, and Legionella pneumophila, all bacteria, and Candida albicans, a yeast (a type of fungus). These organisms were studied because each is an important human pathogen, is commonly found in the hospital environment, and presents difficulties with regard to eradication in that environment.
The microbicidal activity of MDI-P against these organisms was tested at several concentrations and in the presence and absence of human blood serum. In addition, the effects of MDI-P on the morphology of the microbial cells were studied by Gram staining and transmission electron microscopy. Morbidity, mortality, and tissue toxicity were also studied using laboratory mice.
In addition to its microbicidal properties, MDI-P was found to be inexpensive, simple to prepare, apparently harmless to inanimate surfaces, and without significant odor. It retained its microbicidal activity over a pH range from approximately 6.5 to 9. Dr. Baltch's paper also cited other published research regarding the microbicidal activity of MDI-P against bacteria, yeast, and viruses. She called for further testing in order to establish the most useful applications and the exact chemical composition of MDI-P.
MDI-P is a proprietary new (novel) preparation produced by Medical Discoveries, Inc. (MDI) and protected directly or indirectly by eight original U.S. patents, covering both the production and application of the product.
Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies.
Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.
SOURCE: Medical Discoveries, Inc.
Wednesday January 10, 10:36 am Eastern Time
Press Release
SOURCE: Medical Discoveries, Inc. |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Cindy Powell who wrote (192) | 1/17/2001 1:04:57 PM | | From: Cindy Powell | | | | Medical Discoveries, Inc. Receives Eighth Patent
SALT LAKE CITY, Jan. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has received Patent Number 6,117,285 from the United States Patent And Trademark Office, entitled ``System For Carrying Out Sterilization Of Equipment.''
Medical Discoveries, Inc. (MDI) now has a total of eight granted patents relating to the company's proprietary electrolysis devices, methods and the patented products and applications derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, begun in 1992 with proprietary hydrolysis of saline solutions for microbicidal applications and the development of a patented machine to produce these products.
MDI's patents and resulting intellectual properties now span more than a decade of research and development, and include:
Patent No. Patent No. Patent No. Patent No.
5,334,383 5,507,932 5,560,816 5,622,848
"Electrically "Apparatus For "Method For "Electrically
Hydrolyzed Electrolyzing Electrolyzing Hydrolyzed Saline
Salines As Fluids" Fluids" Solutions As
In Vivo [1996] [1996] Microbicides
Microbicides For In Vitro
For Treatment Of Treatment Of
Cardiomyopathy Contaminated
And Multiple Fluids Containing
Sclerosis." Blood"
[1994] [1997]
Patent No. Patent No. Patent No. Patent No.
5,674,537 5,731,008 6,007,686 6,117,285
"An Electrolyzed "Electrically "System For "System For
Saline Solution Hydrolyzed Electrolyzing Carrying Out
Containing Salines As Fluids For Use Sterilization
Concentrated Microbicides" As Antimicrobial Of Equipment"
Amounts Of Ozone [1998] Agents" [2000]
And Chlorine [1999]
Species"
[1997]
The Company has foreign PCT patent applications pending, corresponding to the above-granted United States patents.
Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P.
MDI-P is a solution-based drug, which is produced by the electrolysis of saline, using a patented instrument with proprietary electrodes. This solution has a significant oxidation reduction potential due to a mixture of oxidative products resulting from electrolysis.
Medical Discoveries, Inc. has identified several major target markets for its innovative new drug MDI-P. Each contains opportunities for MDI-P to play a major role in existing and new treatments of major diseases, as well as sterilization and disinfectant applications that represent major advances over current technologies. Medical Discoveries, Inc. intends to move forward in these areas of continued testing and development in the near term, while continuing to research and investigate additional applications for the Company's proprietary technology. MDI intends to vigorously pursue additional patents for its applications while safeguarding the Company's current intellectual properties.
Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies.
Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.
SOURCE: Medical Discoveries, Inc.
Wednesday January 10, 10:40 am Eastern Time
Press Release
SOURCE: Medical Discoveries, Inc. |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Cindy Powell who wrote (193) | 3/31/2001 12:11:54 AM | | From: Cindy Powell | | | | Ninth MDI Patent Expands Security of Basic Technology
SALT LAKE CITY, March 28 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has been notified that Japanese Patent Application Number 508856/96 entitled ``System And Method For Carrying Out Sterilization'' will issue in the near future.
The new patent claims priority to U.S. Patent No. 5,507,932, ``Apparatus For Electrolyzing Fluids,'' issued to Medical Discoveries, Inc. in 1996. This patent was the second in a family of additional patents in the U.S. and elsewhere that defines and safeguards the proprietary electrolysis technology used by MDI.
Once this patent issues, Medical Discoveries, Inc. (MDI) will have a total of nine granted patents relating to the company's proprietary electrolysis devices, methods, and the patented products and application derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, which began in 1992 with proprietary hydrolysis of saline solution for microbicidal applications and the development of a patented machine to produce these products.
Newly allowed Japanese Patent Application Number 508856/96, once issued, will cover similar subject matter in Japan as that claimed in U. S. Patent 5,507,932. Specifically, an apparatus for electrolyzing fluids for in vivo treatment of physiological fluids for the destruction of microbes in warm-blooded animals is claimed. The apparatus can be used with a variety of fluids including whole blood, plasma and cell-containing fluids, without introducing harmful substances into the electrolyzed fluids.
MDI's patents and resulting intellectual properties now span more than a decade of research and development. Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P.
Formed in 1991, Medical Discoveries, Inc. is a public traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications.
Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statement because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.
SOURCE: Medical Discoveries, Inc. |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Cindy Powell who wrote (194) | 6/29/2001 2:28:51 AM | | From: Eye | | | | | Wow, what happened to this company? Stopped watching it a few months ago ... now I see they haven't really gotten anywhere. Not too many people are with the company either and I notice their bigname executive has seemed to have left. Still, it's educational to watch these speculative stocks. I'll go try and catch up on the recent news of MLSC to find out what happened. |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Ellen Sokolow | 8/17/2015 3:59:45 PM | | | | | | The company has been bought by what is now a publicaly available- Redox Supplement. Bought, stabilized and sold to me and you in the form of this liquid. So now, everything that you've already read and heard about here it is available to you directly. This. Is. Amazing. You may message me here or go to lorengraham.teamasea.com for more info. I'm so happy that I found your posts from 2001, Cindy Powell!
Ellen Sokolow |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
